ID
11873
Description
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany
Link
https://clinicaltrials.gov/ct2/show/NCT02419378
Keywords
Versions (3)
- 8/13/15 8/13/15 - Martin Dugas
- 5/24/16 5/24/16 -
- 5/28/16 5/28/16 -
Uploaded on
August 13, 2015
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0 Legacy
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Safety Assessment Multiple Sclerosis ALAIN01 NCT02419378
Safety Assessment Multiple Sclerosis ALAIN01 NCT02419378
- StudyEvent: SE
Description
Safety Lab. Assessments RQG
Description
Safety Lab. Assessments: Date
Data type
date
Description
Safety Lab. Assessments: Date Status
Data type
text
Description
Safety Lab. Assessments: Serum Creatinine
Data type
text
Alias
- UMLS CUI [1]
- C0201976
Description
Safety Lab. Assessments: Platelets
Data type
text
Alias
- UMLS CUI [1]
- C0005821
Description
Safety Lab. Assessments: TSH
Data type
text
Alias
- UMLS CUI [1]
- C0202230
Similar models
Safety Assessment Multiple Sclerosis ALAIN01 NCT02419378
- StudyEvent: SE